Is ISpecimen Stock a Good Investment?

ISpecimen Investment Advice

  ISPC
To provide specific investment advice or recommendations on iSpecimen stock, we recommend investors consider the following general factors when evaluating iSpecimen. This will help you to make an informed decision on whether to include ISpecimen in one of your diversified portfolios:
  • Examine ISpecimen's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
  • Research ISpecimen's leadership team and their track record. Good management can help ISpecimen navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
  • Consider the overall health of the Biotechnology space and any emerging trends that could impact ISpecimen's business and its evolving consumer preferences.
  • Compare ISpecimen's performance and market position to its competitors. Analyze how ISpecimen is positioned in terms of product offerings, innovation, and market share.
  • Check if ISpecimen pays a dividend and its dividend yield and payout ratio.
  • Review what financial analysts are saying about ISpecimen's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in iSpecimen stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if iSpecimen is a good investment.
 
Sell
 
Buy
Strong Sell
We provide advice to complement the regular expert consensus on ISpecimen. Our dynamic recommendation engine utilizes a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. To make sure iSpecimen is not overpriced, please check out all ISpecimen fundamentals, including its total debt, target price, and the relationship between the ebitda and cash flow from operations . Given that iSpecimen has a number of shares shorted of 75.02 K, we strongly advise you to confirm iSpecimen market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your regular risk tolerance and investing horizon.

Market Performance

Very WeakDetails

Volatility

Very riskyDetails

Hype Condition

Under hypedDetails

Current Valuation

UndervaluedDetails

Odds Of Distress

Below AverageDetails

Economic Sensitivity

Very regressive towards the marketDetails

Investor Sentiment

InterestedDetails

Analyst Consensus

Strong BuyDetails

Financial Strenth (F Score)

HealthyDetails

Financial Leverage

Not RatedDetails

Reporting Quality (M-Score)

Unlikely ManipulatorDetails

Examine ISpecimen Stock

Researching ISpecimen's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 15.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.85. Some equities with similar Price to Book (P/B) outperform the market in the long run. iSpecimen recorded a loss per share of 18.12. The entity had not issued any dividends in recent years. The firm had 1:20 split on the 16th of September 2024.
To determine if ISpecimen is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding ISpecimen's research are outlined below:
iSpecimen generated a negative expected return over the last 90 days
iSpecimen has high historical volatility and very poor performance
The company reported the previous year's revenue of 9.93 M. Net Loss for the year was (11.1 M) with profit before overhead, payroll, taxes, and interest of 5.65 M.
iSpecimen currently holds about 23.69 M in cash with (5.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.67.
Roughly 15.0% of the company shares are held by company insiders
Latest headline from finance.yahoo.com: iSpecimen Named Top Competitor in 4.4 Billion USD Market

ISpecimen Quarterly Cash And Short Term Investments

1.75 Million

ISpecimen uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in iSpecimen. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to ISpecimen's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
12th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View
Earnings surprises can significantly impact ISpecimen's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises ISpecimen's investors have experienced.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2022-08-04
2022-06-30-0.27-0.3-0.0311 
2024-05-07
2024-03-31-0.27-0.32-0.0518 
2023-05-04
2023-03-31-0.32-0.270.0515 
2022-02-17
2021-12-31-0.22-0.27-0.0522 
2024-03-13
2023-12-31-0.24-0.32-0.0833 
2023-08-02
2023-06-30-0.3-0.39-0.0930 
2024-07-31
2024-06-30-0.28-0.1860.09433 
2023-11-02
2023-09-30-0.35-0.230.1234 

Know ISpecimen's Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as ISpecimen is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading iSpecimen backward and forwards among themselves. ISpecimen's institutional investor refers to the entity that pools money to purchase ISpecimen's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Millennium Management Llc2024-06-30
0.0
Renaissance Technologies Corp2024-06-30
0.0
Vanguard Group Inc2024-09-30
0.0
Geode Capital Management, Llc2024-09-30
0.0
Main Street Financial Solutions, Llc (pa)2024-09-30
0.0
Sachetta Llc2024-09-30
0.0
Hrt Financial Llc2024-09-30
0.0
Blackrock Inc2024-06-30
56.5 K
Virtu Financial Llc2024-06-30
42.1 K
Jane Street Group Llc2024-06-30
19.9 K
Ubs Group Ag2024-09-30
1.5 K
Note, although ISpecimen's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

ISpecimen's market capitalization trends

The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.05 M.

Market Cap

61.73 Million

ISpecimen's profitablity analysis

Last ReportedProjected for Next Year
Return On Tangible Assets(1.29)(1.36)
Return On Capital Employed(1.14)(1.09)
Return On Assets(0.70)(0.74)
Return On Equity(1.14)(1.08)
The company has Profit Margin (PM) of (0.92) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.64) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.64.
Determining ISpecimen's profitability involves analyzing its financial statements and using various financial metrics to determine if ISpecimen is a good buy. For example, gross profit margin measures ISpecimen's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of ISpecimen's profitability and make more informed investment decisions.
Please note, the presentation of ISpecimen's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ISpecimen's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of ISpecimen's management manipulating its earnings.

Evaluate ISpecimen's management efficiency

iSpecimen has return on total asset (ROA) of (0.4426) % which means that it has lost $0.4426 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0934) %, meaning that it created substantial loss on money invested by shareholders. ISpecimen's management efficiency ratios could be used to measure how well ISpecimen manages its routine affairs as well as how well it operates its assets and liabilities. As of December 4, 2024, Return On Tangible Assets is expected to decline to -1.36. The current year's Return On Capital Employed is expected to grow to -1.09. At present, ISpecimen's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 12.5 M, whereas Non Current Assets Total are forecasted to decline to about 4.1 M.
Last ReportedProjected for Next Year
Book Value Per Share 1.08  1.13 
Tangible Book Value Per Share 0.28  0.29 
Enterprise Value Over EBITDA(9.71)(10.19)
Price Book Value Ratio 9.29  9.76 
Enterprise Value Multiple(9.71)(10.19)
Price Fair Value 9.29  9.76 
Enterprise Value79.5 M51.1 M
Effective leadership at ISpecimen drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Beta
1.593

Basic technical analysis of ISpecimen Stock

As of the 4th of December, ISpecimen retains the Standard Deviation of 9.04, market risk adjusted performance of 0.0214, and Risk Adjusted Performance of 0.0081. ISpecimen technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.

ISpecimen's insider trading activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ISpecimen insiders, such as employees or executives, is commonly permitted as long as it does not rely on ISpecimen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ISpecimen insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

ISpecimen's Outstanding Corporate Bonds

ISpecimen issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. iSpecimen uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ISpecimen bonds can be classified according to their maturity, which is the date when iSpecimen has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Understand ISpecimen's technical and predictive indicators

Using predictive indicators to make investment decisions involves analyzing ISpecimen's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.

Consider ISpecimen's intraday indicators

ISpecimen intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of ISpecimen stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

ISpecimen Corporate Filings

8K
12th of November 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
10Q
7th of November 2024
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
ViewVerify
31st of October 2024
Other Reports
ViewVerify
S1
18th of October 2024
Report filed by companies planning on going public to register their securities with the U.S. Securities and Exchange Commission (SEC)
ViewVerify
ISpecimen time-series forecasting models is one of many ISpecimen's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ISpecimen's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

ISpecimen Stock media impact

Far too much social signal, news, headlines, and media speculation about ISpecimen that are available to investors today. That information is available publicly through ISpecimen media outlets and privately through word of mouth or via ISpecimen internal channels. However, regardless of the origin, that massive amount of ISpecimen data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of ISpecimen news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of ISpecimen relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to ISpecimen's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive ISpecimen alpha.

ISpecimen Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards ISpecimen can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

ISpecimen Corporate Management

When determining whether iSpecimen offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ISpecimen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ispecimen Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ispecimen Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iSpecimen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
For information on how to trade ISpecimen Stock refer to our How to Trade ISpecimen Stock guide.
You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ISpecimen. If investors know ISpecimen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ISpecimen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(18.12)
Revenue Per Share
19.19
Quarterly Revenue Growth
(0.04)
Return On Assets
(0.44)
Return On Equity
(1.09)
The market value of iSpecimen is measured differently than its book value, which is the value of ISpecimen that is recorded on the company's balance sheet. Investors also form their own opinion of ISpecimen's value that differs from its market value or its book value, called intrinsic value, which is ISpecimen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ISpecimen's market value can be influenced by many factors that don't directly affect ISpecimen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between ISpecimen's value and its price, as these two are different measures arrived at by various means. Investors typically determine if ISpecimen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ISpecimen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.